Would they dope? Revisiting the Goldman dilemma

British Journal of Sports Medicine

Volumn 47, Issue 11, 2013, Pages 697-700

  Connor, James ^a   Woolf, Jules ^b   Mazanov, Jason ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF WINDSOR   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ATHLETE; ATTITUDE TO HEALTH; CANADA; DOPING; ELITE PERFORMANCE; FEMALE; HUMAN; MALE; PSYCHOLOGICAL ASPECT; REGRESSION ANALYSIS; TRACK AND FIELD; YOUNG ADULT; PSYCHOLOGY;

DOPING; ELITE PERFORMANCE;

ATHLETES; ATTITUDE TO HEALTH; CANADA; DOPING IN SPORTS; FEMALE; HUMANS; MALE; REGRESSION ANALYSIS; TRACK AND FIELD; YOUNG ADULT;

EID: 84879797727     PISSN: 03063674     EISSN: 14730480     Source Type: Journal    
DOI: 10.1136/bjsports-2012-091826     Document Type: Article

References (31)

1. Goldman B, Bush PJ, Klatz R. Death in the locker room. London: Century, 1984:32.
2. Bamberger M, Yaeger D. Over the edge. Sports Illustrated, 14 April 1997.
3. Bloodworth AJ, Petroczi A, Bailey R, et al. Doping and supplementation: the attitudes of talented young athletes. Scand J Med Sci Sports 2012;22: 293-301.
4. Connor JM, Mazanov J. 'Would you dope? A general population test of the Goldman dilemma'. Br J Sports Med 2009;43: 871-2.
5. Choi BCK, Pak AWP. A catalog of biases in questionnaires. Prev Chronic Dis 2005;2: 1-13.
6. Tourangeau R, Yan T. Sensitive questions in surveys. Psychol Bull 2007;133: 859-83.
7. Fowler FJ. Survey research methods. Thousand Oaks, CA: Sage, 2009: 74-7.
8. de Leeuw ED. To mix or not to mix data collection modes in surveys. J Off Stat 2005;21: 233-55.
9. Voy R. Drugs, sport and politics. Champaign, IL: Leisure Press, 1991.
10. Mazanov J, Petróczi A, Bingham J, et al. Towards an empirical model of performance enhancing supplement use: a pilot study among high performance UK athletes. J Sci Med Sport 2008;11: 185-90. (Pubitemid 351249223)
11. Stamm H, Lamprecht M, Kamber M, et al. The public perception of doping in sport in Switzerland, 1995-2004. J Sports Sci 2008;26: 235-42. (Pubitemid 350302168)
12. Hanstad DV, Loland S. Elite athletes' duty to provide information on their whereabouts: Justifiable anti-doping work or an indefensible surveillance regime? Eur J Sports Sci 2009;9: 3-10.
13. Møldrup C, Traulsen JM, Almasdottir AB. Medically enhanced normality: an alternative prescription on the use of medicines for non-medical purposes. Int J Pharm Pract 2003;11: 243-9. (Pubitemid 37542905)
14. Møldrup C, Hansen RR. Public acceptance of drug use for non-disease conditions. Curr Med Res Opin 2006;22: 775-80.
15. Backhouse S, McKenna J, Robinson S, et al. Attitudes, behaviours, knowledge and education - drugs in sport: past, present and future. Montreal, Canada: World Anti-Doping Agency, 2007.
16. Finley P, Finley L. The sports industry's war on athletes. Westport: Praeger, 2006.
17. Corrigan B, Kazlauskas R. Medication use in athletes selected for doping control at the Sydney Olympics (2000). Clin J Sport Med 2003;13: 33-40. (Pubitemid 36142924)
18. Gucciardi DF, Jalleh G, Donovan R. Does social desirability influence the relationship between doping attitudes and doping susceptibility in athletes? Psychol Sport Exerc 2010;11: 479-86.
19. Huybers T, Mazanov J. What would Kim do: a choice study of projected athlete doping considerations. J Sport Manag 2012;26: 322-34.
20. Parisotto R. Bloodsports. Melbourne, Australia: Hardie Grant Books, 2006.
21. O'Reilly N, Madill J. The World Anti-Doping Agency: the role of social marketing. J Non-Profit Public Sector Mark 2007;17: 1-26.
22. WADA. World anti-doping code. Montreal, Canada: World Anti-Doping Agency, 1999:2009.
23. Hoberman J. 'Athletes in handcuffs?' The criminalisation of doping. In: McNamee M, Moller V, eds. Doping and anti-doping policy in sport. Oxon, UK: Routledge, 2011: 99-110.
24. Erikson PG, Hathaway AD. Normalization and harm reduction: research avenues and policy agendas. Int J Drug Policy 2010;21: 137-9.
25. Sheeran P. Intention-behaviour relations: a conceptual and empirical review. In: Hewstone M, Stroebe W, eds. European review of social psychology. Vol. 12, Chichester, UK: John Wiley & Sons, 2002: 1-36.
26. Connor JM. The athlete as widget: how exploitation explains elite sport. Sport Soc 2009;12: 1369-77.
27. Donovan RJ, Egger G, Kapernick V, et al. A conceptual framework for achieving performance enhancing drug compliance in sport. Sports Med 2002;32: 269-84. (Pubitemid 34293265)
28. Mazanov J, Huybers T. An empirical model of athlete decisions to use performance enhancing drugs: qualitative evidence. Qual Res Sport Exerc 2010;2: 385-402.
29. Petroczi A, Aidman E. Psychological drivers of doping: the life-cycle model of performance enhancement. Subst Abuse Treat Prev Policy 2008;3:7.
30. Stewart B, Smith ACT. Drug use in sport: implications for public policy. J Sport Soc Issues 2008;32: 278-98.
31. Uvascek M, Nepusz T, Mazanov J, et al. Self-admitted behaviour and perceived use of performance enhancing versus psychoactive drugs among competitive athletes. Scand J Med Sci Sports 2011;21: 224-34.